Making the most of insolvency

In the absence of ready investment capital, many German biotechs are facing insolvency. The prospect of buying these companies at bargain prices attracts investors, but German insolvency law is complex, and mistakes on acquisition agreements can be critical.

Download PDF Share Back To Listing
Loading data